Literature DB >> 18371110

Bone marrow trephine morphology and immunohistochemical findings in chronic myelomonocytic leukaemia.

Nye-Thane Ngo1, Irvin A Lampert, Kikkeri N Naresh.   

Abstract

Chronic myelomonocytic leukaemia (CMML) is a clonal disorder with myelodysplastic/myeloproliferative features. Its diagnosis is based on the presence of peripheral blood monocytosis and bone marrow aspirate findings, according to World Health Organization criteria. However, bone marrow trephine biopsy (BMTB) features characteristic of CMML have not been adequately investigated. We studied BMTB in 20 cases of CMML-1 and three cases of CMML-2 and compared with ten cases of polycythaemia vera, ten cases of chronic myeloid leukaemia (chronic phase) and ten cases of florid myeloid hyperplasia (MH). Furthermore, we evaluated the use of CD34, CD117 and CD68 (PGM-1) antibodies in diagnosis and subtyping of CMML and in differentiating from other categories. Hypercellularity, high myeloid:erythroid ratio, increased proportion of 'myelo/monocytic' cells often seen as clusters and/or nodules, absence of eosinophilia, and presence of abnormal localisation of immature precursors (ALIP) and dysmegakaryopoiesis can aid in the diagnosis of CMML in BMTB. CD68 (PGM-1) positive cells amounted to 20.7 +/- 6.1% cells among CMML trephines. The proportion of CD34(+) cells among cases of CMML-1 was </=5% and among CMML-2 was >/=10% cells in two of three cases and 5% in the other case. Morphological and immunohistochemical features of BMTB samples are extremely helpful in the diagnosis of CMML.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18371110     DOI: 10.1111/j.1365-2141.2008.07117.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Morphological evaluation of monocytes and monocyte precursors in bone marrow trephine biopsies - need for establishing diagnostic criteria.

Authors:  Kikkeri N Naresh
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

2.  Cytogenetic risk stratification in chronic myelomonocytic leukemia.

Authors:  Esperanza Such; José Cervera; Dolors Costa; Francesc Solé; Teresa Vallespí; Elisa Luño; Rosa Collado; María J Calasanz; Jesús M Hernández-Rivas; Juan C Cigudosa; Benet Nomdedeu; Mar Mallo; Felix Carbonell; Javier Bueno; María T Ardanaz; Fernando Ramos; Mar Tormo; Reyes Sancho-Tello; Consuelo del Cañizo; Valle Gómez; Victor Marco; Blanca Xicoy; Santiago Bonanad; Carmen Pedro; Teresa Bernal; Guillermo F Sanz
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

3.  Highlights of 2008 in bone marrow biopsy pathology.

Authors:  Jon van der Walt
Journal:  J Hematop       Date:  2009-02-24       Impact factor: 0.196

4.  Abnormal localization of immature precursors (ALIP) detection for early prediction of acute myelocytic leukemia (AML) relapse.

Authors:  Hai-Qing Huang; Xiang-Zhong Fang; Jun Shi; Jie Hu
Journal:  Med Biol Eng Comput       Date:  2013-12-21       Impact factor: 2.602

5.  Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

Authors:  Raphael Itzykson; Pierre Fenaux; David Bowen; Nicholas C P Cross; Jorge Cortes; Theo De Witte; Ulrich Germing; Francesco Onida; Eric Padron; Uwe Platzbecker; Valeria Santini; Guillermo F Sanz; Eric Solary; Arjan Van de Loosdrecht; Luca Malcovati
Journal:  Hemasphere       Date:  2018-11-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.